Repare Therapeutics Inc (RPTX) has released an update.
Repare Therapeutics reports significant clinical progress with its oncology treatments, including a decrease in Grade 3 anemia from its MYTHIC trial and the initiation of a Phase 2 trial for NSCLC expected to produce data by 2025. The company also celebrated the first dosing in its LIONS trial and the appointment of Dr. Steven H. Stein to its Board of Directors. With $237 million in funding, Repare is poised to advance its clinical programs until mid-2026.
For further insights into RPTX stock, check out TipRanks’ Stock Analysis page.
